NASDAQ: GENE - Genetic Technologies Limited

六个月盈利: -4.38%
股息率: 0.00%
部门: Healthcare

促销时间表 Genetic Technologies Limited


关于公司 Genetic Technologies Limited

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

更多详情
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

IPO date 2005-09-02
ISIN US37185R3075
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://genetype.com
Цена ао 0.765
每日价格变化: 0% (0.765)
每周价格变化: 0% (0.765)
每月价格变化: 0% (0.765)
3个月内价格变化: -0.6494% (0.77)
六个月内的价格变化: -4.38% (0.8)
每年价格变化: -71.67% (2.7001)
3年内价格变化: -58.2% (1.83)
5年内价格变化: -79.32% (3.7)
年初以来价格变化: -0.6494% (0.77)

低估

姓名 意义 年级
P/S 44.57 1
P/BV 186.62 1
P/E 0 0
EV/EBITDA -29.87 0
全部的: 1.75

效率

姓名 意义 年级
ROA, % -114.22 0
ROE, % -184.98 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0766 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 77604.62 10
盈利能力 Ebitda, % 87.88 9
盈利能力 EPS, % 8989 10
全部的: 9.2

机构 体积 分享, %
Morgan Stanley 17289 0.45
Rhumbline Advisers 3739 0.1
UBS Group AG 2994 0.08
Wells Fargo & Company 130 0
SIMPLEX TRADING, LLC 18 0



导师 职称 支付 出生年份
Mr. Simon Morriss Chief Executive Officer 262.57k
Mr. Carl S. Stubbings BSc Chief Commercial Officer 173.93k
Mr. Kevin Camilleri Chief Executive Officer of EasyDNA 167.85k
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant 119.53k
Mr. Mark Ziirsen CFO & Company Secretary 1963 (62 年)
Dr. Erika Spaeth Ph.D. Director of Clinical & Scientific Affairs

地址: Australia, Fitzroy, 60-66 Hanover Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://genetype.com